Clinical Trial Results:
A multi-center, randomized, double-blind, placebo-controlled, sequential cohort designed, escalating dose study to assess the tolerability, safety and maximal tolerated dose (MTD) of Ladostigil in patients with mild to moderate Alzheimer's Disease
Summary
|
|
EudraCT number |
2004-004612-23 |
Trial protocol |
ES IT |
Global completion date |
05 Mar 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Mar 2023
|
First version publication date |
04 Mar 2023
|
Other versions |
|
Summary report(s) |
TV3326-201_Results_Summary_Final |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.